NASDAQ:TCRX TScan Therapeutics (TCRX) Stock Price, News & Analysis $0.19 +0.00 (+0.22%) Closing price 04:00 PM EasternExtended Trading$0.18 0.00 (-0.32%) As of 05:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About TScan Therapeutics Stock (NASDAQ:TCRX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get TScan Therapeutics alerts:Sign Up Key Stats Today's Range$0.18▼$0.1950-Day Range$0.17▼$0.6752-Week Range$0.17▼$1.47Volume292,699 shsAverage Volume719,319 shsMarket Capitalization$12.58 millionP/E RatioN/ADividend YieldN/APrice Target$2.67Consensus RatingHold Company Overview TScan Therapeutics, Inc. is a clinical-stage biotechnology company developing T cell receptor-engineered T cell (TCR-T) therapies for cancer. Its approach involves genetically modifying a patient’s T cells to recognize specific cancer-related antigens, with the goal of directing the immune system to attack malignant cells. The company’s pipeline includes investigational therapies for hematologic malignancies and solid tumors. Its lead programs, TSC-100 and TSC-101, are designed to target the HA-1 antigen in patients with certain blood cancers following an allogeneic hematopoietic stem cell transplant. TScan is also advancing additional TCR-T candidates against targets associated with solid tumors through its discovery and development platforms. Founded in 2018 and headquartered in Waltham, Massachusetts, TScan conducts research and clinical development primarily in the United States. Its therapies remain investigational and are not approved for commercial use. The company has been led by Chief Executive Officer David Southwell.AI Generated. May Contain Errors. Read More TScan Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks80th Percentile Overall ScoreTCRX MarketRank™: 3.987697945295 of 5 starsTScan Therapeutics scored higher than 80% of companies evaluated by MarketBeat, and ranked 98th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingHold Consensus RatingTScan Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.14, and is based on no strong buy ratings, 2 buy ratings, 4 hold ratings, and 1 sell rating.Upside PotentialTScan Therapeutics has a consensus price target of $2.67, representing about 1,344.6% upside from its current price of $0.18.Amount of Analyst CoverageTScan Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about TScan Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for TScan Therapeutics are expected to grow in the coming year, from ($0.79) to ($0.65) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of TScan Therapeutics is -0.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of TScan Therapeutics is -0.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTScan Therapeutics has a P/B Ratio of 0.09. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about TScan Therapeutics' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.46% of the float of TScan Therapeutics has been sold short.Short Interest Ratio / Days to CoverTScan Therapeutics has a short interest ratio ("days to cover") of 4.67.Change versus previous monthShort interest in TScan Therapeutics has recently decreased by 11.27%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTScan Therapeutics does not currently pay a dividend.Dividend GrowthTScan Therapeutics does not have a long track record of dividend growth. News and Social Media3.1 / 5News Sentiment0.91 News SentimentTScan Therapeutics has a news sentiment score of 0.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for TScan Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for TCRX on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows2 people have added TScan Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership1.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, TScan Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders13.84% of the stock of TScan Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions82.83% of the stock of TScan Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about TScan Therapeutics' insider trading history. Receive TCRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TScan Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TCRX Stock News HeadlinesTScan Therapeutics (TCRX) Expected to Post Quarterly Earnings on WednesdayNovember 10 at 2:43 AM | americanbankingnews.comTScan Therapeutics Announces Board and Governance ChangesOctober 16, 2026 | tipranks.comI'm handing you this one freeElon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds. He licenses it from one overlooked company. That supplier just got a major catalyst. Musk filed to launch 1,000,000 satellites, a move analyst Dylan believes could drive a 100X bigger bill for this chipmaker starting December 8th.November 11 at 1:00 AM | Behind the Markets (Ad)TScan Therapeutics consensus price target decreased by 55.56% to $2.72September 16, 2026 | msn.comWedbush downgrades TScan Therapeutics (TCRX) to neutral from outperformSeptember 3, 2026 | msn.comTScan Therapeutics Reorganizes To Focus On Solid Tumor Program; To Cut 75% Jobs; Stock Tumbles 11%September 2, 2026 | rttnews.comTScan Therapeutics cuts workforce by 75% and shifts focus to solid tumor programSeptember 2, 2026 | msn.comTScan Reorganizes Pipeline Priorities, Implements Workforce ReductionSeptember 2, 2026 | benzinga.comSee More Headlines TCRX Stock Analysis - Frequently Asked Questions How have TCRX shares performed this year? TScan Therapeutics' stock was trading at $1.00 at the beginning of 2026. Since then, TCRX shares have decreased by 81.5% and is now trading at $0.1846. How were TScan Therapeutics' earnings last quarter? TScan Therapeutics, Inc. (NASDAQ:TCRX) released its earnings results on Wednesday, August, 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.25) by $0.02. The company earned $1.05 million during the quarter, compared to analysts' expectations of $1.88 million. TScan Therapeutics had a negative net margin of 1,655.35% and a negative trailing twelve-month return on equity of 108.72%. When did TScan Therapeutics IPO? TScan Therapeutics (TCRX) raised $107 million in an initial public offering on Thursday, July 15th 2021. The company issued 6,666,667 shares at $15.00-$17.00 per share. How do I buy shares of TScan Therapeutics? Shares of TCRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of TScan Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that TScan Therapeutics investors own include Caribou Biosciences (CRBU), NVIDIA (NVDA), Plug Power (PLUG), Tenaya Therapeutics (TNYA), Perspective Therapeutics (CATX), Iovance Biotherapeutics (IOVA) and Legend Biotech (LEGN). Company Calendar Last Earnings8/12/2026Today11/11/2026Next Earnings (Estimated)11/11/2026EGM 202611/20/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:TCRX CIK1783328 Webwww.tscan.com Phone857-399-9500FaxN/AEmployees142Year Founded2018Price Target and Rating Average Price Target for TScan Therapeutics$2.67 High Price Target$6.00 Low Price Target$1.00 Potential Upside/Downside+1,344.6%Consensus RatingHold Rating Score (0-4)2.14 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($0.91) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$129.77 million Net Margins-1,655.35% Pretax Margin-1,655.35% Return on Equity-108.72% Return on Assets-54.47% Debt Debt-to-Equity Ratio0.31 Current Ratio3.37 Quick Ratio3.37 Sales & Book Value Annual Sales$10.32 million Price / Sales1.21 Cash FlowN/A Price / Cash FlowN/A Book Value$2.16 per share Price / Book0.09Miscellaneous Outstanding Shares67,780,000Free Float58,398,000Market Cap$12.51 million OptionableNot Optionable Beta1.21 Social Links 7 Energy Stocks to Buy and Hold ForeverOil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.Get This Free Report This page (NASDAQ:TCRX) was last updated on 11/11/2026 by MarketBeat.com Staff. From Our PartnersHas The AI Bubble Popped?A recent sell-off wiped $2.3 trillion off the Nasdaq 100 in a single day, leaving Wall Street split on whether...Porter & Company | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredUranium Mine Flood That Sparked a 2006 Price Surge ReturnsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TScan Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TScan Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
